ICA-105574
CAS No. 316146-57-3
ICA-105574( ICA | 3-nitro-N-[4-phenoxyphenyl]-benzamide )
Catalog No. M24250 CAS No. 316146-57-3
ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 88 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 140 | In Stock |
|
| 25MG | 297 | In Stock |
|
| 50MG | 458 | In Stock |
|
| 100MG | 672 | In Stock |
|
| 200MG | 918 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameICA-105574
-
NoteResearch use only, not for human use.
-
Brief DescriptionICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
-
DescriptionICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
-
In Vitro——
-
In Vivo——
-
SynonymsICA | 3-nitro-N-[4-phenoxyphenyl]-benzamide
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorhERG
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number316146-57-3
-
Formula Weight334.33
-
Molecular FormulaC19H14N2O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESC1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Meng J , Shi C , Li L , et al. Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization[J]. European Journal of Pharmacology, 2013, 718(1-3):87-97.
molnova catalog
related products
-
Orphenadrine Citrate
Orphenadrine Citrate is a skeletal muscle relaxant, it acts in the central nervous system to produce its muscle relaxant effects.
-
Lapatinib ditosylate...
Lapatinib ditosylate is an anti-Y drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung Y.
-
Alflutinib
Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.
Cart
sales@molnova.com